Trials / Terminated
TerminatedNCT04502446
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- CRISPR Therapeutics AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
Detailed description
The study may enroll approximately 45 subjects in total.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CTX130 | CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components. |
Timeline
- Start date
- 2020-07-31
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
- First posted
- 2020-08-06
- Last updated
- 2025-01-08
Locations
10 sites across 3 countries: United States, Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04502446. Inclusion in this directory is not an endorsement.